News for Astria Therapeutics, Inc. (ATXS)

[url="]Astria Therapeutics, Inc.[/url] (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

[url="]Astria Therapeutics, Inc.[/url] (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

[url="]Astria Therapeutics, Inc.[/url] (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal trials through 2027. See more here.

On December 31, 2024, Fairmount Funds Management LLC (Trades, Portfolio) executed a significant transaction involving Astria Therapeutics Inc (ATXS). The firm a

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Astria Therapeutics Inc (ATXS). The

[url="]Astria Therapeutics, Inc.[/url] (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Limoneira Company LMNR fell sharply in today's pre-m...

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Monday. Shares of Arm Holdings plc ARM fell sharply in today's pre-mark...

Shares of Rumble Inc.

Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.

[url="]Astria Therapeutics, Inc.[/url] (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

[url="]Astria Therapeutics, Inc.[/url] (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic di

Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find out why ATXS is a Buy.

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

On Wednesday, 311 stocks hit new 52-week lows.

The massacre, stock by stock, all 1001 of them, listed right here.

Read Research Analysts’ Updated EPS Estimates for June 2nd (ADPT, AGLE, AROW, ATDRY, ATXS, AYRWF, BCOR, BIOC, EXAS, GH) at ETF Daily News

Read Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Zacks Investment Research at ETF Daily News